Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.66 |
| ▸ | HTR2A | P28223 | 11/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25420142 | 1.00 | HTR2C (0.66) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25420145 | 1.00 | HTR2C (0.66) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31494797 | 0.87 | HTR2C (0.62) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25630090 | 0.87 | HTR2C (0.62) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25421755 | 0.86 | HTR2C (0.47) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL25421751 | 0.86 | HTR2C (0.47) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL30488390 | 0.86 | HTR2C (0.47) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL25420758 | 0.82 | PPARD (0.50) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL25420756 | 0.82 | PPARD (0.50) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL25630556 | 0.81 | MAOB (0.49) | PPARDPPARAMAOBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051276-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2023114238-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051276-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | GRIN2A, GRIN2C, GAP43 | HTR2C 79/4885HTR2A 74/4885CYP1A2 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.